Literature DB >> 10899953

Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu-opioid receptor (OP(3)) in morphine-pretreated cell.

D Wang1, C K Surratt, W Sadée.   

Abstract

Calmodulin (CaM) has been shown to suppress basal G protein coupling and attenuate agonist-stimulated G protein coupling of the mu-opioid receptor (OP(3)) through direct interaction with the third intracellular (i3) loop of the receptor. Here we have investigated the role of CaM in regulating changes in OP(3)-G protein coupling during morphine treatment, shown to result in CaM release from plasma membranes. Basal and agonist-stimulated G protein coupling by OP(3) was measured before and after morphine pretreatment by incorporation of guanosine 5'-O-(3-[(35)S]thiotriphosphate) into membranes, obtained from HEK 293 cells transfected with human OP(3) cDNA. The opioid antagonist beta-chlornaltrexamine fully suppressed basal G protein coupling of OP(3), providing a direct measure of basal signaling. Pretreatment of the cells with morphine enhanced basal G protein coupling (sensitization). In contrast, agonist-stimulated coupling was diminished (desensitization), resulting in a substantially flattened morphine dose-response curve. To test whether CaM is involved in these changes, we constructed OP(3)-i3 loop mutants with reduced affinity for CaM (K273A, R275A, and K273A/R275A). Basal signaling of these mutant OP(3) receptors was higher than that of the wild-type receptor and, moreover, unaffected by morphine pretreatment, whereas desensitization to agonist stimulation was only slightly attenuated. Therefore, CaM-OP(3) interactions appear to play only a minor role in the desensitization of OP(3). In contrast, release of CaM from the plasma membrane appears to enhance the inherent basal G protein coupling of OP(3), thereby resolving the paradox that OP(3) displays both desensitization and sensitization during morphine treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899953     DOI: 10.1046/j.1471-4159.2000.0750763.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Membrane functional organisation and dynamic of mu-opioid receptors.

Authors:  André Lopez; Laurence Salomé
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

Review 3.  Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins.

Authors:  Ana C Magalhaes; Henry Dunn; Stephen Sg Ferguson
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  YFa and analogs: investigation of opioid receptors in smooth muscle contraction.

Authors:  Krishan Kumar; Ritika Goyal; Annu Mudgal; Anita Mohan; Santosh Pasha
Journal:  World J Gastroenterol       Date:  2011-10-28       Impact factor: 5.742

5.  Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence.

Authors:  Ellen A Walker; Steven N Sterious
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

6.  Relative potency of the opioid antagonists naloxone and 6-alpha-naloxol to precipitate withdrawal from acute morphine dependence varies with time post-antagonist.

Authors:  Gery Schulteis; David Chiang; Clay Archer
Journal:  Pharmacol Biochem Behav       Date:  2008-11-24       Impact factor: 3.533

Review 7.  Opioid receptors and their interacting proteins.

Authors:  Graeme Milligan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 4.103

8.  Constitutive activation of kappa opioid receptors at ventral tegmental area inhibitory synapses following acute stress.

Authors:  Abigail M Polter; Kelsey Barcomb; Rudy W Chen; Paige M Dingess; Nicholas M Graziane; Travis E Brown; Julie A Kauer
Journal:  Elife       Date:  2017-04-12       Impact factor: 8.140

Review 9.  Modulation of opioid receptor function by protein-protein interactions.

Authors:  Konstantinos Alfaras-Melainis; Ivone Gomes; Raphael Rozenfeld; Venetia Zachariou; Lakshmi Devi
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

10.  Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening.

Authors:  Karl Brillet; Brigitte L Kieffer; Dominique Massotte
Journal:  BMC Pharmacol       Date:  2003-12-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.